Loading…

Tevogen Inc.TVGNCompetitor analysis, valuation and peers

United States · USD·Health Care›Pharmaceuticals: Major
Momentum weak 28
Mkt cap
$422M
US dollars, full cap
Free float
100%
of shares outstanding
$/day
$70,932
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
n/a
WACC 6.5%
Hurdle
n/a
no reverse DCF
Next earnings
105 days
3 Mar 2027
Close · USD$6.14
1D+7.9%
1W+2.3%
1M-10.0%
3M-4.4%
6M-37.8%
YTD-62.9%
1Y-70.6%
ATR %9.4%
Beta1.42
52w lowhigh75.3% off high

What Tevogen does

Employees: 18

Tevogen at a glance

Size Tevogen (TVGN) is a United States Health Care company (Pharmaceuticals: Major) with a market value of $422M, the 2798th largest of 3,085 United States companies the cockpit tracks. Shares closed at $6.14 on 18 Nov 2026.

Performance Over six months the shares fell 37.8%, against -20.4% for the median peer and -2.2% for the United States market (cap-weighted) — 7th lowest of 21 in its peer set.

Next results Next results expected around 3 Mar 2027 (exchange calendar; dates can move).

Relative performance

507510021 May 202621 Aug 202618 Nov 2026Peer median 82TVGN 59
Six months, rebased to 100: Tevogen against the median of its 20 peers (local-currency closes).

Tevogen financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$0$0$0$0$0
Revenue growth—————
Gross profit-$250,228-$509,197-$403,581-$378,357$0
EBITDA-$22.3M-$25.6M-$53.2M-$8.46M-$953,080
Net income-$22.9M-$26.3M-$10.1M-$60.5M$4.41M
Free cash flow-$9.94M-$12.4M-$12.0M-$8.30M-$215,400
Capital expenditure$64,439$64,439$0$133,000$0
Total debt$10.4M$7.50M$2.89M$95.4M$0

Quarterly statements and history in the cockpit →

Tevogen competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-40%-20%0%+20%-20%-10%0%6031390010606010894114048410002728OVIDZOTA600613002923PHAT7871RZLT688117605077688136CTMX002864000518000788TVGN6-month return →1-month return →
Up and to the right = strong over both horizons. Tevogen is the large dot.

Tevogen competitors and peer comparison

How Tevogen compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Tevogen against its 20 peers (data as of 18 Nov 2026)
MeasureTVGNPeer medianRank in peer set
1-month return-10.0%-13.0%9th highest of 21
6-month return-37.8%-20.4%7th lowest of 21
Distance from 52-week high-75.3%-47.7%2nd lowest of 21

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Tevogen TVGNUnited States$422M-38%n/an/an/an/an/a
Shaanxi Kanghui Pharmaceutical Co 603139.SSChina$421M-31%+1%-39%7.1×n/an/a
JW Pharmaceutical 001060.KSSouth Korea$423M-26%+9%13%0.7×-15.4%+7.2%
Beijing Foyou Pharma 601089.SSChina$423M-27%+5%10%0.2×n/an/a
Synmosa Biopharma 4114.TWOTaiwan$423M-1%+21%10%2.2×5.4%+15.3%
Hyundai Bioscience 048410.KSSouth Korea$424M-50%+78%-580%164.0×n/an/a
Teyi Pharmaceutical 002728.SZChina$419M-12%-7%7%3.2×24.4%+8.0%
Ovid Therapeutics OVIDUnited States$427M-5%-78%-4,700%208.3×n/an/a
Zota Health Care ZOTA.NSIndia$427M+9%+69%-16%6.2×n/an/a
Shanghai Shenqi Pharmaceutical Investment Management 600613.SSChina$427M+4%-4%3%1.2×10.6%+1.4%
Zhuhai Rundu Pharmaceutical 002923.SZChina$430M-30%+14%5%2.2×1.4%-1.3%
Phathom Pharmaceuticals PHATUnited States$431M-55%+87%-9%2.9×n/an/a
Elixiron Immunotherapeutics (Cayman) 7871.TWOTaiwan$412M+64%+6,162%-194%119.7×n/an/a
Rezolute RZLTUnited States$411M+32%n/an/an/an/an/a
Cheng Du Sheng Nuo Biotec 688117.SSChina$433M-48%+51%27%3.4×-0.2%+14.5%
Zhejiang Huakang Pharmaceutical 605077.SSChina$433M-47%+35%4%1.1×n/an/a
Kexing Biopharm 688136.SSChina$433M-42%-14%-12%2.9×n/an/a
CytomX Therapeutics CTMXUnited States$410M-49%-88%-676%4.7×n/an/a
Shaanxi Panlong Pharmaceutical 002864.SZChina$407M-15%-16%7%1.7×-3.2%+11.2%
Jiangsu Sihuan Bioengineering 000518.SZChina$437M-8%-17%-28%10.6×n/an/a
PKU Healthcare 000788.SZChina$437M-12%-49%5%2.1×-5.6%-5.6%

Questions

Which companies are Tevogen's closest peers?
The cockpit's peer set: Shaanxi Kanghui Pharmaceutical Co (603139.SS), JW Pharmaceutical (001060.KS), Beijing Foyou Pharma (601089.SS), Synmosa Biopharma (4114.TWO), Hyundai Bioscience (048410.KS), Teyi Pharmaceutical (002728.SZ), Ovid Therapeutics (OVID), Zota Health Care (ZOTA.NS).
How has Tevogen stock performed?
Over six months to 18 Nov 2026 the shares returned -37.8% against -20.4% for the median peer; over one year -70.6%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.